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Abstract
Few antibiotic options exist for the management of infections due to vancomycin-resistant 
enterococci (VRE). We describe a case involving the safe and successful use of tedizolid, a new 
oxazolidinone, to treat VRE prosthetic joint infection.
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Vancomycin-resistant enterococci (VRE) have become increasingly frequent and 
challenging to treat. From 2003 to 2006, hospitalizations with VRE-related infection more 
than doubled, and as of 2009, VRE was the second most common cause of nosocomial 
infection in the U.S. [1, 2]. Furthermore, vancomycin resistance is present in up to 79 
percent of Enterococcus faecium isolates [2].
Currently, one antibiotic, linezolid, an oxazolidinone, is approved by the U.S. Food and 
Drug Administration (FDA) for the treatment of infections due to VRE. Tedizolid, a next-
generation oxazolidinone currently FDA-approved for acute bacterial skin and skin-structure 
infections, including those caused by Enterococcus faecalis but not E. faecium exhibits 
broad-spectrum activity against the majority of Gram-positive organisms, including VRE. 
Here, we present a case describing the novel, unlabeled use of tedizolid for a prolonged 
period (4 weeks) to treat a prosthetic joint infection (PJI) due to vancomycin-resistant E. 
faecium.
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A 51-year-old woman with a history of total right hip arthroplasty (THA) 17 months prior, 
complicated by recurrent PJI, presented with rhabdomyolysis after 2 weeks of treatment 
with daptomycin. Following her initial right THA, she had developed recurrent PJI due to a 
number of different organisms, requiring explantation of her prosthesis, 5 subsequent 
surgical incision and debridements, and multiple courses of antimicrobial therapy (Figure 1). 
Intraoperative cultures were positive for several pathogens: vancomycin-sensitive E. faecalis, 
coagulase-negative staphylococci, and Pseudomonas aeruginosa. However, intraoperative 
cultures collected from the patient’s acetabulum and hip fascia during the most recent 
debridement yielded coagulase-negative staphylococci and vancomycin-resistant E. faecium, 
susceptible to daptomycin, linezolid, doxycycline, and quinupristin-dalfopristin (Table 1). 
Gram stain performed on these specimens did not reveal any polymorphonuclear leukocytes 
or microorganisms. Daptomycin was started 2 weeks prior to her presentation with a 
significant reduction in the pain and swelling of her affected hip. Unfortunately, she 
developed severe pain in both forearms and was diagnosed with rhabdomyolysis with a peak 
serum creatine kinase level > 28,000 units/L. Daptomycin was promptly discontinued and 
her rhabdomyolysis resolved.
In light of the susceptibility of the isolated E. faecium to linezolid, the patient was started on 
tedizolid 200 mg PO once daily. Her past psychiatric history was notable for major 
depression and anxiety, for which she was prescribed venlafaxine, amitriptyline, and 
doxepin. These were discontinued as a precaution upon discussion with her primary care 
physician prior to receiving tedizolid. The patient was continued on ciprofloxacin to treat the 
previously isolated P. aeruginosa. In total, the patient was treated with tedizolid in an 
inpatient setting for 28 days with significant clinical improvement in her PJI and a reduction 
in her serum C-reactive protein from 35.1 mg/L (before the start of daptomycin) to 4.1 mg/L 
at discharge. At no point did she manifest symptoms of serotonin syndrome or treatment-
related thrombocytopenia. At four-month follow-up after discontinuation of tedizolid, she 
had no clinical signs of relapse of VRE PJI and has not received chronic suppressive 
antibiotic therapy. A joint aspiration was not performed after completion of treatment with 
tedizolid.
DISCUSSION
This case demonstrates the successful use of tedizolid to treat vancomycin-resistant E. 
faecium PJI. Although enterococci are responsible for only a small fraction (about 3–10%) 
of PJIs, the emergence of VRE presents a significant therapeutic challenge [3, 4]. Tedizolid 
is an attractive candidate for the treatment of VRE, surpassing linezolid for several reasons. 
In vitro, tedizolid may be a more potent drug, with several-fold lower minimum inhibitory 
concentrations (MIC) against VRE than linezolid [5]. Furthermore, tedizolid appears to 
retain activity against linezolid- and daptomycin-resistant enterococci, displaying MIC 
values on average 4- to 8-fold lower compared to linezolid [6]. Commerical methods for 
antimicrobial susceptibility testing of tedizolid are not routinely available, and there are no 
interpretive criteria for defining susceptibility in E. faecium. In this case, susceptibility of 
the VRE to tedizolid was inferred from the isolate’s susceptibility to linezolid, as linezolid 
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susceptibility has been shown to be highly predictive of tedizolid susceptibility. In one study, 
99.8% of enterococcal isolates that were susceptible to linezolid were also susceptible to 
tedizolid [7]. Finally, tedizolid may be better tolerated than linezolid, with several studies 
suggesting a significantly lower risk of serotonin syndrome and thrombocytopenia compared 
to linezolid [8–10].
Little is known regarding the use or efficacy of tedizolid in the treatment of PJI. No studies 
have investigated the penetration of tedizolid into synovial fluid or bone to date. The 
effectiveness of tedizolid against staphylococci isolated from prosthetic joint infections was 
assayed in one study [11]. All isolates of Staphylococcus aureus and Staphylococcus 
epidermidis were susceptible to tedizolid in a planktonic state, but against isolates in a 
biofilm state, MICs for tedizolid were ~1–2 dilutions higher. This pattern was similarly 
observed for vancomycin as well. Yet, the clinical improvement of our patient may be 
evidence that tedizolid reaches adequate killing concentrations in bone and synovium.
Specific guidelines do not exist for the optimal management of PJI caused by VRE, although 
daptomycin and linezolid are often used and are recommended for the treatment of PJI due 
to penicillin-resistant enterococci [12]. Tedizolid should be considered as an alternative 
agent to treat VRE PJI in the setting of antibiotic resistance, medication intolerance, or 
potential drug-drug interactions.
CONCLUSION
Our case describes the novel, successful, and unlabeled use of tedizolid in the treatment of 
PJI secondary to vancomycin-resistant E. faecium. The safe, extended duration (4 weeks) of 
treatment suggests that tedizolid can be used for managing infections requiring prolonged 
therapy such as PJI, with the potential for less hematological toxicity and risk of interaction 
with serotonergic agents compared to linezolid. Further research is warranted to better 
characterize the clinical efficacy of tedizolid against VRE in PJI and other osteoarticular 
infections.
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Case timeline, including surgeries, operative cultures, and antimicrobial therapy.
CONS: coagulase-negative staphylococci
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Table 1
Antimicrobial susceptibility of Enterococcus faecium isolated from intraoperative culture, as determined by 
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